Orion - Other information disclosed according to the rules of the Exchange

146,000 Orion Corporation A shares converted into B shares

ORION CORPORATION      STOCK EXCHANGE RELEASE 1 AUGUST 2017 at 9.00 a.m.
EEST


146,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion
Corporation, 146,000 A shares have been converted into 146,000 B shares. The
conversion has been entered into the Trade Register on 1 August 2017.

The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 37,120,346 A shares and 104,137,482 B shares. The number
of votes of the company's shares is after the conversion 846 544 402.



Orion Corporation



 Olli Huotari               Jari Karlson
 SVP, Corporate Functions   CFO




Contact person:
Mari Lautsuo, Communications Manager, tel. +358 10 426 2156



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish pharmaceutical company - a builder of
well-being. Orion develops, manufactures and markets human and veterinary
pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The
company is continuously developing new drugs and treatment methods. The core
therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS)
disorders, oncology and respiratory for which Orion developes inhaled Easyhaler®
pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the
company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq
Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.



[]